Adjuvant EGFR TKI therapy for resectable non-small cell lung cancer: new era for personalized medicine

Documenti analoghi

• Adjuvant treatment with EGFR TKI in resected non-small cell lung cancer with EGFR mutation: all that glitters is not gold!
  di: Fiorelli, Alfonso, et al.
  Pubblicazione: (2020)
• Adjuvant TKI therapy in resected EGFR-mutant non-small-cell lung cancer—ready for prime time?
  di: Arulananda, Surein, et al.
  Pubblicazione: (2020)
• EGFR-TKI-based vs non-EGFR-TKI-based adjuvant therapy in resected non-small-cell lung cancer with EGFR mutations: a meta-analysis of randomized controlled trials
  di: Wu, Jing-Xun, et al.
  Pubblicazione: (2018)
• Adjuvant bevacizumab for resected non-small cell lung cancer: the end of an era?
  di: Mountzios, Giannis
  Pubblicazione: (2018)
• Erlotinib as standard adjuvant therapy for resectable EGFR mutation-positive non-small cell lung cancer
  di: Tanaka, Satomi, et al.
  Pubblicazione: (2019)